Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays
Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays
复制标题
DOI：
10.1210/jc.2011-0254
复制
发表时间：
2011-07-01
影响因子：
5.8
通讯作者：
Kumar, Rajiv
中科院分区：
文献类型：
--
作者：
McNulty, Melissa;Singh, Ravinder J.;Kumar, Rajiv
背景：硬化蛋白改变骨形成。生物样品中sclerostin浓度的精确和可重复测量对于评估代谢性骨病是重要的。我们使用两种市售的ELISA测定血清和血浆中的sclerostin浓度。方法：我们使用两种市售的ELISA测定从25名正常人受试者获得的血清或肝素-血浆中的sclerostin浓度，所述ELISA可从Biomedica Medizinprodukte GmbH和TECOmedical AG获得。使用Biomedica测定，血清硬化蛋白浓度为0.99 +/-0.12 ng/ml（平均值+/- SEM），血浆浓度为1.47 +/-0.13 ng/ml（配对t检验，P < 0.001）。使用TECO测定，血清硬化蛋白水平为0.71 +/-0.05ng/ml，血浆硬化蛋白浓度为0.80 +/-0.06ng/ml（配对t检验，P < 0.001）。当通过两种测定法测定时，血清和血浆硬化蛋白浓度显著不同（血清，P < 0.015;血浆，P < 0.001）。加入重组硬化素的回收率低于Biomedica和TECO测定法的预期值（P < 0.001，配对t检验）。应谨慎解释当前检测的血清或血浆sclerostin浓度。数据表明，相同的测定应用于比较患者组或纵向随访的患者。在被引入一般临床实验室使用之前，需要对sclerostin测定进行标准化。（临床内分泌代谢杂志96：E1159-E1162，2011）
Background: Sclerostin alters bone formation. The precise and reproducible measurement of sclerostin concentrations in biological samples is important for assessment of metabolic bone disease. We determined sclerostin concentrations in serum and plasma using two commercially available ELISA.Methods: We measured sclerostin concentrations in serum or heparin-plasma obtained from 25 normal human subjects using two commercial ELISA available from Biomedica Medizinprodukte GmbH and TECOmedical AG.Results: With the Biomedica assay, serum sclerostin concentrations were 0.99 +/- 0.12 ng/ml (mean +/- SEM), and plasma concentrations were 1.47 +/- 0.13 ng/ml (paired t test, P < 0.001). With the TECO assay, serum sclerostin levels were 0.71 +/- 0.05 ng/ml, and plasma sclerostin concentrations were 0.80 +/- 0.06 ng/ml (paired t test, P < 0.001). Serum and plasma sclerostin concentrations were significantly different when determined by the two assays (serum, P < 0.015; plasma, P < 0.001). Recovery of added recombinant sclerostin to serum was less than expected with both Biomedica and TECO assays (P < 0.001, paired t test).Conclusions: The concentrations of sclerostin in serum and plasma are different when determined by the two assays. Serum or plasma sclerostin concentrations with current assays should be interpreted with caution. The data suggest that the same assay should be used for comparing groups of patients or patients being followed longitudinally. Standardization of sclerostin assays is required before being introduced into general clinical laboratory use. (J Clin Endocrinol Metab 96: E1159-E1162, 2011)